Literature DB >> 11295037

Indomethacin and telomerase activity in tumor growth retardation.

C Lönnroth1, M Andersson, K Lundholm.   

Abstract

It is well-recognized that cycloogygenase inhibitors attenuate tumor growth in tumor models, although underlying mechanisms are unclear. In the present study we report that indomethacin retards MCG-101 tumor growth on mice by induction of apoptosis/necrosis and inhibits telomere elongation. The inhibition of telomerase activity by NSAIDs (indomethacin, mobic, sulindac sulfone, suramin) was, however, not a universal finding, since a mouse melanoma (K1735-M2) did not respond. By contrast, a human cell line of colon carcinoma origin (HT-29), responded by both retarded growth and telomerase activity despite a low intrinsic production of prostaglandins, mainly PGE2. Therefore, it is not likely that indomethacin inhibition of tumor growth and telomere elongation is directly related to Cox-1/Cox-2 activities in tumor cells. Also, NSAIDs at 25 microM (sulindac sulfone) decreased growth and telomerase activity in MCG-101 cells, without any effects on PGE2 production, while ibuprofen reduced PGE2 production but had no effect on growth or telomerase activity. Our results demonstrate that cyclooxygenase inhibitors can retard tumor growth both in murine tumors and in human tumor cells by inhibition of telomerase activity in addition to previously recognized mechanisms as induction of apoptosis, inhibition of cell proliferation, influence on the expression of growth factors around growing tumors and attenuation of neoangiogenesis.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11295037

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  10 in total

Review 1.  Crosstalk of oncogenic and prostanoid signaling pathways.

Authors:  Rolf Müller
Journal:  J Cancer Res Clin Oncol       Date:  2004-06-15       Impact factor: 4.553

2.  Two-dimensional polyacrylamide gel electrophoresis analysis of indomethacin-treated human colon cancer cells.

Authors:  Yan-Li Cheng; Gui-Ying Zhang; Zhi-Qiang Xiao; Fa-Qing Tang
Journal:  World J Gastroenterol       Date:  2005-04-28       Impact factor: 5.742

Review 3.  New drugs for the anorexia-cachexia syndrome.

Authors:  Mellar P Davis
Journal:  Curr Oncol Rep       Date:  2002-05       Impact factor: 5.075

4.  Preoperative treatment with a non-steroidal anti-inflammatory drug (NSAID) increases tumor tissue infiltration of seemingly activated immune cells in colorectal cancer.

Authors:  Christina Lönnroth; Marianne Andersson; Annette Arvidsson; Svante Nordgren; Hans Brevinge; Kristina Lagerstedt; Kent Lundholm
Journal:  Cancer Immun       Date:  2008-02-29

5.  Survival and erythropoietin receptor protein in tumours from patients randomly treated with rhEPO for palliative care.

Authors:  Christina Lönnroth; Marie Svensson; Wenhua Wang; Ulla Körner; Peter Daneryd; Ola Nilsson; Kent Lundholm
Journal:  Med Oncol       Date:  2007-09-11       Impact factor: 3.064

6.  Screening for novel protein targets of indomethacin in HCT116 human colon cancer cells using proteomics.

Authors:  Yan-Li Cheng; Gui-Ying Zhang; Cui Li; Jing Lin
Journal:  Oncol Lett       Date:  2013-09-03       Impact factor: 2.967

7.  Global tumor RNA expression in early establishment of experimental tumor growth and related angiogenesis following COX-inhibition evaluated by microarray analysis.

Authors:  Hans Axelsson; Christina Lönnroth; Marianne Andersson; Wenhua Wang; Kent Lundholm
Journal:  Cancer Inform       Date:  2007-05-01

8.  Suramin increased telomerase activity in the c6 glioma/wistar experimental brain tumor model.

Authors:  Mine Ergüven; Ayhan Bilir; Tuncay Altug; Fadime Aktar; Nuriye Akev
Journal:  Int J Biomed Sci       Date:  2007-06

9.  Formulation of indomethacin colon targeted delivery systems using polysaccharides as carriers by applying liquisolid technique.

Authors:  Kadria A Elkhodairy; Hanna A Elsaghir; Amal M Al-Subayiel
Journal:  Biomed Res Int       Date:  2014-05-26       Impact factor: 3.411

10.  The expression of COX-2, hTERT, MDM2, LATS2 and S100A2 in different types of non-small cell lung cancer (NSCLC).

Authors:  Mojca Strazisar; Vid Mlakar; Damjan Glavac
Journal:  Cell Mol Biol Lett       Date:  2009-02-23       Impact factor: 5.787

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.